Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases

Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results

(2017) M. Danova et al.   JOURNAL OF CLINICAL ONCOLOGY

Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer

(2010) David N. Church et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

(2008) I. H. Park et al.   ANNALS OF ONCOLOGY

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

(2008) S. Dawood et al.   ANNALS OF ONCOLOGY

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases

(2008) Raffaele Addeo et al.   CANCER

Survival in patients with brain metastases from breast cancer

(2008) April F. Eichler et al.   CANCER

Results of the Phase III ENRICH (RT-016) Study of Efaproxiral Administered Concurrent with Whole Brain Radiation Therapy (WBRT) in Women with Brain Metastases from Breast Cancer

(2008) J.H. Suh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2008) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival

(2008) Michelle E. Melisko et al.   JOURNAL OF NEURO-ONCOLOGY